Skip to content
God Of Sound – Lifestyle
Author:
NEUROCRINE BIOSCIENCES, INC.
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2026 Financial Results
October 12, 2026
Neurocrine Biosciences to Present Research Advancing Understanding of Prader-Willi Syndrome and Real-World Experience with VYKAT® XR (diazoxide choline) at Foundation for Prader-Willi Research Symposium & Family Conference
September 30, 2026
Neurocrine Biosciences to Present at Upcoming Investor Conferences in September
September 2, 2026
Neurocrine Biosciences Announces Publication of KINECT-PRO™ Findings Demonstrating INGREZZA® (valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily Functioning for People Living with Tardive Dyskinesia
August 12, 2026
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-‘1968, a GLP-1/GIP/Glucagon Receptor Triple Agonist
August 7, 2026
Neurocrine Biosciences Reports Second-Quarter 2026 Financial Results
July 30, 2026
Neurocrine Biosciences Announces Key Leadership Hiring, Promotions
July 23, 2026
Neurocrine Biosciences Appoints Samir Siddhanti Chief Business Officer
July 21, 2026
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2026 Financial Results
July 9, 2026
Neurocrine Biosciences Initiates Phase 2 Study of Crinecerfont in Pediatric Patients Under 4 Years Old with Classic Congenital Adrenal Hyperplasia
July 1, 2026
1
2
3
Next Page
→